Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Expert Opin Ther Targets. 2014 Apr 21;18(7):725–730. doi: 10.1517/14728222.2014.909414

Novel genetic targets in endometrial cancer

Daphne W Bell 1
PMCID: PMC4128487  NIHMSID: NIHMS614773  PMID: 24750045

Abstract

Worldwide, ~74,000 women die from endometrial cancer each year. Understanding the somatic genomic alterations that drive endometrial tumorigenesis may provide new opportunities to identify targeted therapies for specific subsets of patients.

Since 2012, the use of next generation sequencing to decode the mutational landscape of endometrial tumors has not only confirmed prior knowledge of established genetic targets for serous and endometrioid endometrial carcinomas, but has also uncovered novel significantly mutated genes, referred to herein as novel genetic targets, which represent candidate cancer genes in these tumors. This editorial summarizes the novel genetic targets that have been identified in serous and endometrioid ECs, according to their unifying functional characteristics. An expert opinion section comments on remaining knowledge gaps that will undoubtedly be filled in future genomic studies of endometrial cancer.

1. Introduction

Most endometrial cancers are endometrial carcinomas (ECs), which are further classified into numerous histopathological subtypes including endometrioid and serous ECs (reviewed in [1]). Endometrioid tumors account for ~80% of newly diagnosed ECs. Although they have a good overall prognosis, improved therapeutic strategies are needed to treat recurrent and advanced-stage endometrioid tumors. Likewise, alternative therapeutic approaches are needed for the treatment of serous ECs, which have a poor overall prognosis. In the era of precision medicine, comprehensive interrogations of tumor exomes and genomes for somatic alterations have been driven by the hope that they will reveal novel genetic targets that might ultimately guide treatment. For the purposes of this editorial, the consideration of novel genetic targets is limited to mutated genes; other classes of genomic and epigenomic alterations also represent novel genetic targets but are beyond the scope of this discussion.

2. Novel genetic targets in endometrioid and serous ECs

Recent massively parallel sequencing of endometrioid and serous ECs by individual laboratories [2-6], and by The Cancer Genome Atlas (TCGA) [7], has uncovered novel, statistically significantly mutated genes (SMGs) in these tumors; that is, genes that are mutated at a statistically significantly higher rate than background and which therefore represent candidate cancer genes. Furthermore, the integrated genomic analysis of endometrioid and serous ECs by TCGA revealed that they can be reclassified into four distinct molecular subgroups: ultramutated/POLE-mutant, hypermutated/microsatellite instability (MSI), copy number low/microsatellite stable (MSS), and copy number high/serous-like [7]. The abundance of SMGs in the ultramutated subgroup precludes their discussion in this Editorial. Among the remaining three subgroups, 32 SMGs, including 20 novel genetic targets (Table 1), have been described [7]. For ease of discussion herein, these novel genetic targets are loosely categorized according to their major ascribed functions.

Table 1.

Mutation frequency of novel significantly mutated protein-encoding genes identified among serous and non-ultramutated endometrioid ECs

Gene
symbol
Frequency of somatic mutations§ Reference
Histological subtype Molecular subgroup [7]
Endometrioid Serous Ultramutated Hypermutated/
MSI
Copy number
low/MSS
Copy number
high/serous-
like
ARID5B 9%-18% 0% 47% 23% 6% 0% [6, 7]
BCOR 4%-10% 0% 65% 17% 7% 0% [6, 7]
CHD4 7%-13% 13%-
18%
65% 6% 12% 13% [3, 4, 6, 7]
CSDE1 7% 0% 59% 15% 1% 0% [7]
CTCF 15%-29% 0% 41% 23% 21% 0% [6, 7, 9]
FBXW7 7%-27% 20%-
29%
82% 9% 6% 22% [2-4, 6, 7]
GIGYF2 8%-14% 6% 59% 20% 0% 7% [6, 7]
HIST1H2BD 2% 0% 0% 8% 1% 0% [7]
LIMCH1 6%-9% 0% 53% 12% 0% 0% [6, 7]
MECOM 4% 0% 24% 5% 4% 0% [7]
METTL14 3% 0% 24% 5% 3% 0% [7]
NKAP 4% 0% 18% 11% 1% 0% [6, 7]
RBMX 4% 0% 24% 12% 0% 0% [7]
RPL22 10%-52% 0% 29% 37% 0% 0% [7, 21]
SGK1 4% 2% 35% 3% 6% 2% [7]
SOX17 2% 0% 0% 0% 8% 0% [7]
SPOP 0%-6% 4%-8% 29% 6% 10% 5% [3, 4, 6, 7]
TAF1 11%-27% 4%-9% 82% 25% 1% 5% [4, 6, 7]
TNFAIP6 2% 0% 29% 2% 1% 0% [7]
ZFHX3 13%-36% 6% 82% 31% 2% 7% [6, 7]
§

Mutation frequencies for the TCGA dataset were obtained from Kandoth et al [7] and via the cBioPortal for Cancer Genomics [32, 33]

CSMD3 is a novel SMG in EC but is not shown in Table 1 because it may be a false-positive

¶ MIR1277 is significantly mutated but is not shown in Table 1 because it is not a protein-encoding gene

2.1 Transcriptional regulation

Six novel SMGs, CTCF, ZFHX3, SOX17, BCOR, MECOM, and TAF1, encode transcriptional regulators. CTCF (CCCTC-binding factor) encodes a zinc-finger transcription factor that regulates transcriptional activation and repression, and influences chromatin architecture (Reviewed in [8]). Frequent truncating mutations within CTCF in MSI+ endometrioid ECs, and the unstable nature of the truncated transcripts, has lead to the proposal that CTCF may be a haploinsufficient tumor suppressor gene in these tumors [9]. Another transcription factor gene, ZFHX3 (Zinc Finger Homeobox 3), is significantly mutated in hypermutated/MSI ECs [7]. ZFHX3 is a putative tumor suppressor gene based on its location within a common region of 16q22 deletion in human cancer and the occurrence of frequent somatic mutations in prostate cancer [10]. SOX17 (SRY (sex determining region Y)-box 17), a SMG in copy number low/MSS ECs, encodes an HMG box transcription factor that, amongst other effects, negatively regulates WNT/β-catenin signaling [11]. In copy number low/MSS ECs, SOX17 mutations are mutually exclusive with other genetic aberrations affecting the WNT/β-catenin pathway, suggesting that they likely perturb WNT signaling [7]. BCOR (BCL6 corepressor), which encodes a corepressor of BCL6, is significantly mutated in copy number low/MSS ECs [7]. MECOM (MDS1 and EVI1 Complex Locus), a protooncogene that encodes a zinc finger transcription factor, is significantly mutated in copy number low/MSS ECs [7]. Although the functional impact of MECOM mutations in EC is unknown, it is noteworthy that MECOM inhibitors are being developed [12]. Finally, TAF1 (TAF1 RNA Polymerase II, TATA Box Binding Protein (TBP)-Associated Factor, 250kDa) encodes a subunit of the TFIID basal transcription factor and is a SMG in serous EC [4].

2.2 Chromatin remodeling and chromatin organization

CHD4 (chromodomain helicase DNA binding protein 4) and ARID5B (AT rich interactive domain 5B (MRF1-like)) are novel SMGs involved in chromatin remodeling [3, 7]. CHD4 was first implicated in EC by virtue of its designation as a SMG in serous tumors [3]. CHD4 is a subunit of the NuRD complex, which is a transcriptional activator and repressor, and is implicated in the DNA damage response [13]. ARID5B (AT rich interactive domain 5B (MRF1-like) is a SMG in hypermutated/MSI ECs and encodes a DNA-binding protein that complexes with PHF2 (PHD finger protein 2), a lysine demethylase. The DNA-binding activity of ARID5B is believed to direct the ARID5B-PHF2 complex to specific gene promoters resulting in histone demethylation and transcriptional activation [14]. Another SMG in hypermutated/MSI ECs is HIST1H2BD (histone cluster 1, H2bd), which encodes a core component of the nucleosome.

2.3 Ubiquitin-mediated protein degradation

FBXW7 (F-Box And WD Repeat Domain Containing 7, E3 Ubiquitin Protein Ligase) and SPOP (Speckle-Type POZ Protein), which encode the substrate recognition components of the SKP1-CUL1-FBXW7 and SPOP-CUL3 ubiquitin ligase complexes respectively, are SMGs in serous ECs [2-4]. FBXW7 is a bona fide tumor suppressor and SPOP is a putative tumor suppressor. Many of the FBXW7 mutations documented in EC encode dominant-negative or loss-of -function mutants in other tumor types and it is therefore anticipated that SPOP mutations in EC may function similarly [3]. In certain cellular contexts, loss of FBXW7 function is associated with in vitro sensitivity to sorafenib and resistance to antitubulin chemotherapeutics (reviewed in [15]), or sensitivity to an HDAC inhibitor [16]. However, the relevance of those observations to FBXW7-mutant endometrial cancers remains to be elucidated.

2.4 RNA binding or RNA modification

Four novel genetic targets, RPL22, RBMX, CSDE1, and METTL14, have RNA binding capability or RNA modification activity. RPL22 (Ribosomal Protein L22) encodes a ribosomal protein and is believed to be a tumor suppressor gene in T-ALL [17]. RPL22 mutations are extraordinarily frequent (52%) in MSI+ EECs, and are attributed to a recurrent frameshift mutation (c.43delA) suggesting loss of function [18]. RBMX (RNA binding motif protein, X-linked) encodes an RNA-binding protein that regulates pre-mRNA splicing [19], and is implicated in the DNA damage response [20], mitotic sister chromatid cohesion [21], and the regulation of Tumor Necrosis Factor Receptor 1 release. RBMX is a SMG in hypermutated/MSI ECs, exhibiting recurrent in-frame deletions encompassing the translation start site. CSDE1 (cold shock domain containing E1, RNA-binding), a SMG in hypermutated/MSI EC, encodes an RNA- and single-stranded DNA-binding protein that regulates mRNA turnover and translation (reviewed in [22]). Most CSDE1 mutations in EC are missense mutations, including three recurrently mutated residues (R174, R726, R774). Finally, METTL14 (Methyltransferase Like 14) is significantly mutated in hypermutated/MSI ECs [7], and encodes a methyltransferase that complexes with METTL3 and methylates m6A on nuclear RNA [23]. The majority of METTL14 mutations in EC are missense mutations within the methyltransferase domain, including a recurrent R298P mutation [7].

2.5 Other functions

NKAP, GIGYF2, LIMCH1, TNFAIP6, and SGK1 are novel genetic targets that do not precisely fit into the previously discussed categories. NKAP (NFKB Activating Protein) regulates NF kappa B activation induced by TNF and IL-1 [24], is a transcriptional corepressor for Notch [25], and has been implicated in RNA splicing [26]. NKAP is significantly mutated in hypermutated/MSI ECs [7]. GIGYF2 (GRB10 Interacting GYF Protein 2), encoded by a SMG in hypermutated/MSI ECs, is involved in IGF-I receptor signaling [27], and is implicated in the regulation of protein translation [28]. LIMCH1 (LIM and Calponin Homology Domains 1) encodes a protein with a poorly defined function and is significantly mutated in hypermutated/MSI ECs [7]. The R421fs frameshift mutation accounts for almost all LIMCH1 mutations in hypermutated/MSI ECs and is predicted to encode a truncated protein lacking the LIM domain. TNFAIP6 (Tumor necrosis factor, alpha-induced protein 6) is significantly mutated in hypermutated/MSI ECs. The encoded protein interacts with components of the extracellular matrix including hyaluronan [29], and is involved in the inflammatory response and tissue remodeling [30]. Finally, SGK1 (Serum/glucocorticoid regulated kinase 1), a SMG in copy number low/MSS ECs, encodes a kinase implicated in the regulation of a wide range of cellular processes including tumor cell survival. Although SGK1 has received attention as a potential druggable target in cancer (reviewed in [31]), the biological and therapeutic relevance of SGK1 mutations in EC remain unknown.

3. Mutation patterns between SMGs

Patterns of mutations between genes can provide insights into their possible functional effects. Here, the pattern of mutations among the 32 SMGs, identified in non-ultramutated ECs in TCGA, was obtained via the cBioPortal for Cancer Genomics [32, 33] (Supplementary Tables 1-4). As shown in Table 2, mutations in a number of novel SMGs showed a tendency for mutually exclusive or co-occurring mutations, suggesting, respectively, possible functional redundancy or cooperativity.

Table 2.

Statistically significant trends in mutation patterns§ involving novel SMGs identified in non-ultramutated ECs in the TCGA study [7]

Molecular Subgroup Gene Pair Trend in Mutation Pattern § p-value§
Hypermutated/MSI ARID5B-ZFHX3 Co-occurrence 0.035
CTCF-FGFR2 Co-occurrence 0.025
FBXW7-LIMCH1 Co-occurrence 0.021
BCOR- PPP2R1A Co-occurrence 0.006
HIST1H2BD -RPL22 Co-occurrence 0.005
SPOP-RPL22 Co-occurrence 0.016
SPOP-CCND1 Co-occurrence 0.005
SPOP-PPP2R1A Co-occurrence 0.040
MECOM-PPP2R1A Co-occurrence 0.021
MECOM-ATR Co-occurrence 0.0004
METTL14-FGFR2 Co-occurrence 0.048
METTL14-PPP2R1A Co-occurrence 0.021
SGK1-RBMX Co-occurrence 0.013
TNFAIP6-MECOM Co-occurrence 0.046
TNFAIP6-METTL14 Co-occurrence 0.046
Copy number low/MSS SPOP-PTEN Mutual exclusivity 0.029
SOX17-CTNNB1 Mutual exclusivity 0.043
FBXW7-CTNNB1 Mutual exclusivity 0.022
FBXW7-SOX17 Co-occurrence 0.047
MECOM-PIK3R1 Co-occurrence 0.011
Copy number high/serous-like CHD4-FBXW7 Co-occurrence 0.009
GIGYF2-TP53 Mutual exclusivity 0.001
Ultramutated ZFHX3-PIK3CA Co-occurrence 0.015
ZFHX3-ATR Co-occurrence 0.029
GIGYF2-CSDE1 Co-occurrence 0.004
SGK1-CTNNB1 Co-occurrence 0.017
ATR-CTNNB1 Co-occurrence 0.017
CSDE1-FGFR2 Co-occurrence 0.041
GIGYF2-FGFR2 Co-occurrence 0.041
LIMCH1-PPP2R1A Co-occurrence 0.020
SPOP-KRAS Mutual exclusivity 0.009
RBMX-KRAS Mutual exclusivity 0.029
CCND1-RPL22 Co-occurrence 0.014
§

Data were obtained from the cBioCancer Genomics Portal [32,33]; SMGs identified in the ultramutated subgroup were not included in the input query. Only gene-pairs demonstrating a p-value <0.05, as derived via Fisher's Exact test are shown; p-values are not adjusted for FDR.

4. Expert opinion

With novel genetic targets for serous and endometrioid EC now in hand, the challenge will be to determine whether any of these targets are therapeutically relevant. This can take the form of biochemical and biological studies of mutant proteins in their proper cellular and genetic context, systems biology approaches to functionalize the genome [5], as well as systematic searches for gene-drug interactions. One strategy to prioritize genetic targets for further analysis is to focus on the most frequently mutated of the SMGs, which, if proven to be druggable, would theoretically maximize the number of patients who might gain clinical benefit. Alternatively, SMGs that have reported gene-drug interactions and/or are being evaluated as druggable targets in preclinical studies within other cellular contexts, such as FBXW7, MECOM, and SGK1, could be prioritized for assessment of their therapeutic relevance to EC. In terms of seeking druggable targets, it is noteworthy that catalogues of SMGs are dynamic rather than static and depend on the assumptions and parameters used in statistical calculations as well as user-defined statistical cut-offs. Moreover, current catalogues of genetic targets in serous and endometrioid ECs have principally been derived from analyses of primary tumor tissues resected prior to treatment. As such, there may be additional genetic targets yet to be discovered within recurrent or persistent tumors that are refractory to therapy, or in metastatic disease. Additionally, the genomic landscape of other histological subtypes of endometrial carcinoma remains to be elucidated. Finally, it remains to be seen whether additional novel genetic targets will emerge from sequencing of larger numbers of tumors corresponding to each of the four recently defined molecular subgroups of serous and endometrioid EC.

Supplementary Material

Supplementary Table 1
Supplementary Table 2
Supplementary Table 3
Supplementary Table 4

References

  • 1.Dedes KJ, Wetterskog D, Ashworth A, et al. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol. 2011;8:261–71. doi: 10.1038/nrclinonc.2010.216. • This article provides an excellent review of targeted therapies currently being evaluated for endometrial cancer. [DOI] [PubMed] [Google Scholar]
  • 2.Kuhn E, Wu RC, Guan B, et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst. 2012;104:1503–1513. doi: 10.1093/jnci/djs345. • The first published whole exome sequencing analysis of serous endometrial carcinomas, which documented high-frequency somatic mutations in the FBXW7 tumor suppressor gene. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Le Gallo M, O'Hara AJ, Rudd ML, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet. 2012;44:1310–15. doi: 10.1038/ng.2455. • This study identified somatic mutations in serous endomerial carcinomas using whole exome sequencing, and extended their analysis of novel candidate driver genes to both clear cell and endometrioid endometrial carcinomas; this was the first study to identify the chromatin remodelling gene CHD4, and the ubiquitin ligase complex gene SPOP as candidate driver genes in serous tumors. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Zhao S, Choi M, Overton JD, et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. ProcA Natl Acad Sci USA. 2013;110:2916–21. doi: 10.1073/pnas.1222577110. • This study describes the systematic identification of somatic mutations and copy number alterations among a large series of serous endometrial carcinomas and cell lines. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Liang H, Cheung LW, Li J, et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 2012;22:2120–9. doi: 10.1101/gr.137596.112. • This study employed a unique systems biology approach to search for pathogenic driver genes in endometrial carcinomas. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kinde I, Bettegowda C, Wang Y, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013;5:167–164. doi: 10.1126/scitranslmed.3004952. • This manuscript highlights the potential utility of molecular based diagnostics for endometrial cancer. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73. doi: 10.1038/nature12113. •• Landmark study reporting the genomic and epigenomic landscape of endometrioid and serous endometrial carcinomas. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lee BK, Iyer VR. Genome-wide studies of CCCTC-binding factor (CTCF) and cohesin provide insight into chromatin structure and regulation. J Biol Chem. 2012;287:30906–13. doi: 10.1074/jbc.R111.324962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Zighelboim I, Mutch DG, Knapp A, et al. High frequency strand slippage mutations in CTCF in MSI-positive endometrial cancers. Hum Mutat. 2014;35:63–5. doi: 10.1002/humu.22463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Sun X, Frierson HF, Chen C, et al. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet. 2005;37:407–12. doi: 10.1038/ng1528. [DOI] [PubMed] [Google Scholar]
  • 11.Sinner D, Kordich JJ, Spence JR, et al. Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol. 2007;27:7802–15. doi: 10.1128/MCB.02179-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Zhang Y, Sicot G, Cui X, Vogel M, Wuertzer CA, Lezon-Geyda K, Wheeler J, Harki DA, Muzikar KA, Stolper DA, et al. Targeting a DNA binding motif of the EVI1 protein by a pyrrole-imidazole polyamide. Biochemistry. 2011;50:10431–41. doi: 10.1021/bi200962u. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.O'Shaughnessy A, Hendrich B. CHD4 in the DNA-damage response and cell cycle progression: not so NuRDy now. Biochem Soc Trans. 2013;41:777–82. doi: 10.1042/BST20130027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Baba A, Ohtake F, Okuno Y, et al. PKA-dependent regulation of the histone lysine demethylase complex PHF2-ARID5B. Nat Cell Biol. 2011;13:668–75. doi: 10.1038/ncb2228. [DOI] [PubMed] [Google Scholar]
  • 15.Inuzuka H, Fukushima H, Shaik S, Liu P, Lau AW, Wei W. Mcl-1 ubiquitination and destruction. Oncotarget. 2011;2:239–44. doi: 10.18632/oncotarget.242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483:570–5. doi: 10.1038/nature11005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Rao S, Lee SY, Gutierrez A, et al. Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. Blood. 2012;120:3764–73. doi: 10.1182/blood-2012-03-415349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Novetsky AP, Zighelboim I, Thompson DM, Jr., et al. Frequent mutations in the RPL22 gene and its clinical and functional implications. Gynecol Oncol. 2013;128:470–4. doi: 10.1016/j.ygyno.2012.10.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Heinrich B, Zhang Z, Raitskin O, et al. Heterogeneous nuclear ribonucleoprotein G regulates splice site selection by binding to CC(A/C)-rich regions in pre-mRNA. J Biol Chem. 2009;284:14303–15. doi: 10.1074/jbc.M901026200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Adamson B, Smogorzewska A, Sigoillot FD, et al. A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. Nat Cell Biol. 2012;14:318–28. doi: 10.1038/ncb2426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Matsunaga S, Takata H, Morimoto A, et al. RBMX: a regulator for maintenance and centromeric protection of sister chromatid cohesion. Cell Rep. 2012;1:299–308. doi: 10.1016/j.celrep.2012.02.005. [DOI] [PubMed] [Google Scholar]
  • 22.Mihailovich M, Militti C, Gabaldon T, et al. Eukaryotic cold shock domain proteins: highly versatile regulators of gene expression. Bioessays. 2010;32:109–18. doi: 10.1002/bies.200900122. [DOI] [PubMed] [Google Scholar]
  • 23.Liu J, Yue Y, Han D, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N(6)-adenosine methylation. Nat Chem Biol. 2014;10:93–5. doi: 10.1038/nchembio.1432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Chen D, Li Z, Yang Q, et al. Identification of a nuclear protein that promotes NF-kappaB activation. Biochem Biophys Res Commun. 2003;310:720–4. doi: 10.1016/j.bbrc.2003.09.074. [DOI] [PubMed] [Google Scholar]
  • 25.Pajerowski AG, Nguyen C, Aghajanian H, et al. NKAP is a transcriptional repressor of notch signaling and is required for T cell development. Immunity. 2009;30:696–707. doi: 10.1016/j.immuni.2009.02.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Burgute BD, Peche VS, Steckelberg AL, et al. NKAP is a novel RS-related protein that interacts with RNA and RNA binding proteins. Nucleic Acids Res. 2014;42:3177–93. doi: 10.1093/nar/gkt1311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Giovannone B, Lee E, Laviola L, et al. Two novel proteins that are linked to insulin-like growth factor (IGF-I) receptors by the Grb10 adapter and modulate IGF-I signaling. J Biol Chem. 2003;278:31564–73. doi: 10.1074/jbc.M211572200. [DOI] [PubMed] [Google Scholar]
  • 28.Morita M, Ler LW, Fabian MR, et al. A novel 4EHP-GIGYF2 translational repressor complex is essential for mammalian development. Mol Cell Biol. 2012;32:3585–93. doi: 10.1128/MCB.00455-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Lee TH, Wisniewski HG, Vilcek J. A novel secretory tumor necrosis factor-inducible protein (TSG-6) is a member of the family of hyaluronate binding proteins, closely related to the adhesion receptor CD44. J Cell Biol. 1992;116:545–57. doi: 10.1083/jcb.116.2.545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Milner CM, Higman VA, Day AJ. TSG-6: a pluripotent inflammatory mediator? Biochem Soc Trans. 2006;34:446–50. doi: 10.1042/BST0340446. Pt 3. [DOI] [PubMed] [Google Scholar]
  • 31.Lang F, Voelkl J. Therapeutic potential of serum and glucocorticoid inducible kinase inhibition. Expert Opin Investig Drugs. 2013;22:701–14. doi: 10.1517/13543784.2013.778971. [DOI] [PubMed] [Google Scholar]
  • 32.Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–404. doi: 10.1158/2159-8290.CD-12-0095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Sci Signal. 2013;6:pl1. doi: 10.1126/scisignal.2004088. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Table 1
Supplementary Table 2
Supplementary Table 3
Supplementary Table 4

RESOURCES